Allergy Therapeutics plc (AIM: AGY), a fully integrated commercial biotechnology company specialising in allergy immunotherapies, has announced a proposed cancellation of its ordinary shares from trading on AIM, alongside plans to re-register as a private limited company. The company's board has unanimously recommended both resolutions, citing disproportionate listing costs exceeding £1 million per annum and limited free float of approximately 9%. Shareholders will vote on the proposals at an AGM to be held on 14 December 2026, with cancellation expected to take effect at 7:00 a.m. on 22 December 2026 if approved.

Key Points

  • Allergy Therapeutics plc (AIM: AGY) — fully integrated allergy immunotherapy biotechnology company
  • Board proposes cancellation of AIM admission and re-registration as a private limited company
  • AIM cancellation expected at 7:00 a.m. on 22 December 2026 if the special resolution passes; re-registration expected the week commencing 11 January 2027
  • Investors should watch the 14 December 2026 AGM vote and the introduction of the JP Jenkins matched bargain trading facility post-cancellation

Why Allergy Therapeutics Is Seeking to Leave AIM After Shareholder Refinancings

The board states that refinancings undertaken over the last 18 months with its three largest shareholders — SkyGem Acquisitions Limited, Southern Fox Investments, and Hayfin Healthcare Opportunities LuxCo S.à r.l — have left only approximately 9% of ordinary shares in public hands. The announcement states that this lack of free float, combined with wider market liquidity challenges, is negatively affecting the company's share price. Average daily trading volume over the 12 months to 16 November 2026 was approximately 444,544 ordinary shares, representing approximately 0.01% of issued share capital, the disclosure shows.

Annual Listing Costs Exceed £1 Million as Board Cites Regulatory Burden

The board has identified ongoing AIM-related costs in excess of £1 million per annum, encompassing nominated adviser and broker fees, London Stock Exchange fees, and associated legal, audit, registrar, financial public relations, and non-executive director costs. The announcement states the directors believe these funds could be better directed towards the group's working capital and growth plans. Management time spent on regulatory obligations is also cited as a factor, with the board concluding that a private structure would allow faster strategic decision-making and potentially improved access to funding on better terms.

SkyGem and Southern Fox, Holding 87.98% Combined, Commit to Supporting Resolutions

The board has received oral commitments from SkyGem and Southern Fox, which together hold 87.98% of issued shares, that they intend to vote in favour of both the cancellation and re-registration resolutions. Under AIM Rules, each resolution requires approval by shareholders holding at least 75% of votes cast. The directors themselves intend to vote in favour across an aggregate of 9,167,707 ordinary shares, representing approximately 0.14% of issued ordinary share capital. Following cancellation, four independent non-executive directors — Cheryl MacDiarmid, Tunde Otulana, David Ball, and Lawrence Allen Wang — will step down from the board.

JP Jenkins Matched Bargain Facility to Provide Post-Cancellation Liquidity for AGY Shareholders

To address the needs of shareholders who may wish to trade after the AIM cancellation, Allergy Therapeutics has arranged a matched bargain trading facility through JP Jenkins, an FCA-authorised firm. The facility, which will operate for a minimum of 12 months following cancellation, allows shareholders to leave buy or sell indications via their stockbroker, with trades executed if a matching order is found. A trading fee of 1.5% applies, subject to a minimum charge of £25 per trade. The announcement notes there is no guarantee of liquidity or that shareholders will be able to realise their investment through the facility.